Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.

Cedric Francois

Pascal Deschatelets

Apellis Pharmaceuticals, Inc.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Sarepta Therapeutics, Inc.

At Apellis, we are committed to developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body’s immune system. Our work is rooted centrally at C3, which is the only target in the complement cascade that addresses all three pathways that can drive disease. Targeting C3 has broad platform potential to treat many diseases where patients have few or no treatment options available. Our programs across ophthalmology, nephrology, hematology, and neurology are further exploring what is possible by targeting C3. You can view our community guidelines here: Community guidelines: http://bit.ly/476Q8

Solasta Ventures

Sectoral Asset Management

Cormorant Asset Management

Epidarex Capital

F-Prime Capital

Vivo Capital

Clough Capital Partners

Sofinnova Investments

venBio Partners

Morningside Venture Investments

Morningside Ventures

Apellis Pharmaceuticals

There are over 7,000 rare diseases, and only 5% of them have an approved treatment. We take pride in supporting patients like Ashley, who is living with #PNH, a rare and potentially life-threatening blood disease.

Learn more about our commitment to the rare disease community: https://bit.ly/4baXFv2 #WeAreApellis

At Apellis, our values are not just how we operate. They’re who we are. 

Learn more about what makes our Apellis culture special: https://bit.ly/3S2LVC2 #WeAreApellis

We’re pleased to share a preliminary fourth quarter and full year revenue update. Apellis CEO Cedric Francois will be discussing these updates and our 2024 priorities today at the J.P. Morgan Healthcare Conference at 9:45 a.m. PT. 

Read more: https://bit.ly/3NWft30 #JPM24 $APLS

Mark your calendar – Apellis CEO Cedric Francois will be presenting at #JPM24 on Monday, January 8! Learn more: https://bit.ly/48jYbVL

At Apellis, our science starts with the complement cascade. The complement cascade may be activated by 3 pathways, all converging at C3. C3 controls all downstream effects that can drive disease: cell removal, inflammation & cell death or dysregulation. 

Learn more: https://lnkd.in/gaUxCxFu

Today, we announced an update on the ongoing regulatory review of our geographic atrophy treatment in the European Union. https://bit.ly/3REfRVY

We are proud to share new data that reinforce the long-term efficacy and safety our paroxysmal nocturnal hemoglobinuria (#PNH) treatment. These post hoc data were presented over the weekend at the American Society of Hematology Annual Meeting. #ASH23

https://bit.ly/3Njb4GY

At Apellis, our values are the roadmap for people, guiding every decision, and every action we take. Each year, we celebrate Apellucians who go above and beyond to live by these values in our annual awards ceremony. Join us in celebrating them! #WeAreApellis

Did you know it's #GeographicAtrophy (GA) Awareness week? GA is the dry, advanced form of #AMD. This hits close to home for Henry Winkler whose father-in-law, Ed, experienced AMD. Learn more about GA and our partnership at GAwontwait.com. #WeAreApellis

We’re proud to support the inaugural World #GeographicAtrophy (GA) Day in partnership with BrightFocus Foundation, Macular Society, Fighting Blindness Canada and Prevent Blindness 🌍 

Help us raise awareness and provide support for the 5 million people worldwide living with GA. #WorldGADay #WeAreApellis

Metric
Company Name	Apellis Pharmaceuticals, Inc.	Sarepta Therapeutics, Inc.
Symbol	APLS	SRPT
MSH ID	COM:APELLIS	COM:SAREPTA
Market	STOCKS	STOCKS
Sector	Healthcare	Healthcare
Industry	Biotechnology	Biotechnology
Country	US	US
Stage		Post-IPO Equity
Employee Count	702	1.31K
Website	apellis.com	sarepta.com
LinkedIn	apellis
Founders

Metric
Market Cap	4.54B	14.11B
Enterprise Value
Monthly Web Traffic		12.98K
Web Traffic Growth		-0.26
Valuation
Raised Capital		5.96M

Metric
Revenue	396.59M	1.24B
Revenue (LTM)
Revenue (NTM)
Gross Profit	336.38M	1.09B
EBITDA	-515.42M	-267.82M
Operating Income	-517.12M	-267.82M
Net Income	-528.63M	-535.98M
EPS	-4.45	-5.80
Diluted EPS	-4.45	-5.80
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.86	0.88
Operating Profit Margin	-0.53	0.03
EBITDA Margin	-1.30	-0.22
Net Profit Margin	-0.54	0.03
Return on Equity	-1.39	0.05
Return on Assets	-0.37	0.01
Return on Capital Employed	-0.44	0.01

COM:APELLIS

Apellis Pharmaceuticals, Inc.

Last Close

27.75

22/11 21:00

Market Cap

4.54B

Beta: -

Volume Today

2.66M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-13.43	-16.13
P/B Ratio	35.03	14.58
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	17.50	11.03
EV Multiple	-9.71	207.35

Metric
Days Sales Outstanding	260.84	117.02
Days Payables Outstanding	159.91	234.37
Days Inventory Outstanding	913.04	958.33
Operating Cycle	1.11K	1.05K
Cash Conversion Cycle	886.42	841.56
Asset Turnover	0.68	0.44

Metric
Operating Cash Flow	-594.74M	-500.99M
Free Cash Flow	-595.51M	-588.34M
Cash Flow to Debt	-0.88	-0.32
Operating Cash Flow/Sales	-0.66	-0.26
Free Cash Flow Yield	-0.08	-0.05

Metric
Cash & Equivalents	352.30M	428.43M
Accounts Receivable	-198.72M	-185.70M
Inventory	146.36M	322.86M
Goodwill
Debt to Capitalization	0.64	0.59
Debt to Assets	0.13	0.54
Current Ratio	4.29	5.44
Quick Ratio	4.18	3.44

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.40	0.17
R&D to Revenue	1.47	0.81
SG&A to Revenue	1.69	0.43